



Published on *Drug Pipeline* (<https://www.drugpipeline.net>)

Home > Gonorrhea - Pipeline Review, H1 2019

---

## Gonorrhea - Pipeline Review, H1 2019

**Publication ID:**

GMD0319020

**Publication Date:**

March 18, 2019

**Pages:**

111

**Publisher:**

Global Markets Direct

**Region:**

Global [1]

**\$2,000.00**

Publication License Type \*

Single User License (PDF), \$2,000.00

Site License (PDF), \$4,000.00

Global License (PDF), \$6,000.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

Add to cart



**Description:**

Gonorrhea - Pipeline Review, H1 2019

## Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gonorrhea - Pipeline Review, H1 2019, provides an overview of the Gonorrhea (Infectious Disease) pipeline landscape.

Gonorrhea is a sexually transmitted disease (STD) caused by *Neisseria gonorrhoeae* bacterium. It can infect both males and females. The bacteria target the cells of the mucous membranes including surfaces of the urethra, vagina, cervix and endometrium, lining of the eyelid, the throat and fallopian tubes. Symptoms include painful urination, pus-like discharge from penis, increased vaginal discharge, abdominal pain and pelvic pain. Treatment includes antibiotics.

## Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gonorrhea - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Gonorrhea (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gonorrhea (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Gonorrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical, Discovery and Unknown stages are 2, 2, 10, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively.

Gonorrhea (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Gonorrhea (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Gonorrhea (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific

sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gonorrhea (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gonorrhea (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gonorrhea (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gonorrhea (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gonorrhea (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

### **Table Of Contents:**

Table of Contents

Introduction

Gonorrhea - Overview

Gonorrhea - Therapeutics Development

Gonorrhea - Therapeutics Assessment

Gonorrhea - Companies Involved in Therapeutics Development

Gonorrhea - Drug Profiles

Gonorrhea - Dormant Projects

Gonorrhea - Discontinued Products

Gonorrhea - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Gonorrhea, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Gonorrhea - Pipeline by Biolytics Pharma, H1 2019

Gonorrhea - Pipeline by Debiopharm International SA, H1 2019

Gonorrhea - Pipeline by Entasis Therapeutics Inc, H1 2019

Gonorrhea - Pipeline by Evofem Biosciences Inc, H1 2019

Gonorrhea - Pipeline by GlaxoSmithKline Plc, H1 2019

Gonorrhea - Pipeline by Hsiri Therapeutics LLC, H1 2019

Gonorrhea - Pipeline by Melinta Therapeutics Inc, H1 2019

Gonorrhea - Pipeline by Merck & Co Inc, H1 2019

Gonorrhea - Pipeline by Microbiotix Inc, H1 2019

Gonorrhea - Pipeline by Paratek Pharmaceuticals Inc, H1 2019

Gonorrhea - Pipeline by Pharmiva AB, H1 2019

Gonorrhea - Pipeline by Redx Pharma Plc, H1 2019

Gonorrhea - Pipeline by Spero Therapeutics Inc, H1 2019

Gonorrhea - Pipeline by Summit Therapeutics Plc, H1 2019

Gonorrhea - Dormant Projects, H1 2019

Gonorrhea - Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Gonorrhea, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

### **Companies Mentioned:**

Biolytics Pharma

Debiopharm International SA

Entasis Therapeutics Inc

Evofem Biosciences Inc

GlaxoSmithKline Plc

Hsiri Therapeutics LLC

Melinta Therapeutics Inc

Merck & Co Inc

Microbiotix Inc

Paratek Pharmaceuticals Inc

Pharmiva AB

Redx Pharma Plc

Spero Therapeutics Inc

Summit Therapeutics Plc

### **License Types:**

#### Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

#### Site License (PDF)\*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional

office.

- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

## Global License (PDF)\*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

\*If Applicable.



No. 1101, Golden Square, 3rd Floor,  
24th Main, J P Nagar, 1st Phase,  
Bangalore, Karnataka, India- 560078

India: +91-8762746600

info@domain.com

-->

## NAVIGATE

About Us

Reports by Region

FAQ

Privacy Policy

TERMS & CONDITIONS

CONTACT

## RECENT POSTS

What is drug pipeline research?

March 20

How to use market research to bring your idea to life?

March 11

How to gain business insights using syndicated market research?

March 10

---

Source URL: <https://www.drugpipeline.net/global-markets-direct/gonorrhea-pipeline-review-h1-2019>

Links

[1] <https://www.drugpipeline.net/region/global>